Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Phase 1/2

HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction

NCT07123779 · tracked via the Priya Life Science USA tracker
Sponsor
35Pharma Inc., a GSK company
Phase
Phase 1/2
Started
2026-10-21
Last updated
2026-10-30

Condition(s) studied

Pulmonary HypertensionHeart Failure With Preserved Ejection Fraction

Investigational drug(s) / intervention(s)

HS235 →Placebo

HS235: Subcutaneous Injection

Placebo: Subcutaneous Injection

Study summary

Study of HS235 in Overweight and Obese Participants with Combined Pre and Post-Capillary Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: Participants are eligible to be included in the study only if they meet at least all the following criteria: 1. Male or female, ≥ 18 years of age. 2. \[Sub-population A only - using a remote PAP sensor\]- Ambulatory PAP monitoring (e.g., CardioMEMS™ HF System or Cordella™ HF System) implanted in the course of standard of care at least 90 days before Screening. Hemodynamic evidence of PH with: 1. mPAP ≥ 25 mm Hg, as measured by the ambulatory PAP monitoring system in supine position by the averaged 7-day values (weekly average) 2 weeks and 1 week before Randomization AND, 2. dPAP ≥ 15 mm Hg, as measured by the ambulatory PAP monitoring system in supine position by the averaged 7-day values (weekly average) 2 weeks and 1 week before Randomization. 3. Hemodynamic evidence of pre-capillary PH based on presence of PVR ≥ 240 dyn\*sec/cm5 or ≥ 3 WU obtained on most recent RHC obtained prior to screening. 3. \[Sub-population B only - without a remote PAP sensor\] Hemodynamic evidence of Cpc-PH based on the presence of all the following RHC parameters obtained during the Screening period, prior to randomization: 1. PVR ≥ 240 dyn\*sec/cm5 or ≥ 3 WU, and 2. mPAP \> 20 mmHg, and 3. PAWP \> 15 mmHg but \< 30 mmHg, and 4. dPAP ≥ 15 mmHg. 4. Established diagnosis of HFpEF with left ventricular ejection fraction (LVEF) ≥ 45 % as measured by echocardiography during Screening and and no documented LVEF \< 45% during the 2 years preceding Screening.. 5. New York Heart Association (NYHA) class II or III heart failure symptoms. 6. Stable diuretic regimen during the screening period. 7. Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) \< 90 at screening. 8. 6-minute walking distance (6MWD) ≥ 100 m at screening. 9. Body mass index ≥ 25 to ≤ 50 kg/m2 and Body weight ≤140 kg. 10. Ability to adhere to study visit schedule and understand and comply with all protocol requirements. Exclusion Criteria: 1. Hospitalization for any worsening medical condition or major surgery within 4 weeks prior to screening. 2. Occurrence of an acute coronary syndrome, percutaneous coronary intervention, or cardiac surgery within 90 days prior to Screening. 3. Implantation of a cardiac resynchronization therapy (CRT) device within 90 days before screening. 4. Planned cardiovascular revascularization or planned implantation of CRT device. 5. History of heart transplant or on heart transplant list. 6. History of serious or life-threatening cardiac arrhythmia within 90 days prior to screening. 7. Systemic hypotension or uncontrolled systemic hypertension. 8. History of Pericardial constriction or hypertrophic cardiomyopathy. 9. History of significant valvular stenosis or regurgitation. 10. Participants with a pneumonectomy or more than moderate Chronic Obstructive Pulmonary Disease (COPD) or mild interstitial lung disease (ILD) or untreated mild obstructive sleep apnea (OSA).

Primary outcome measure(s)

  • Incidence and Number of Adverse Events (AEs) — Up to 85 weeks
    An AE is any untoward medical occurrence in a participant or clinical trial participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The incidence and number of participants who experience an AE will be reported.

Trial sites (3)

FacilityCityRegionStatus
Investigational Site-105 Kansas City Missouri Recruiting
Investigational Site-101 Greenville South Carolina Recruiting
Investigational Site-103 Dallas Texas Recruiting

More 35Pharma Inc., a GSK company trials in the USA

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07123779 on ClinicalTrials.gov ↗ ← All trials in the USA